The global stem cell therapy is developing rapidly, and it is expected to reach 400 billion dollars in 2020.
The stem cell industry chain includes upstream collection, preparation and preservation, midstream differentiation and appreciation, preparation development and downstream clinical treatment and application. The global stem cell industry chain, with steady growth in the upstream and the fastest development in the downstream, has entered a period of rapid development in clinical treatment. The scale of global stem cell industry continues to expand, and according to IMS prediction, it will reach 400 billion US dollars by 2020. The basic research of stem cell industry in China ranks first in the world, with about 2,500 stem cell patents, ranking second in the world. The industry started late, but developed rapidly. It is estimated that the scale will reach 654.38+020 billion RMB by 2020.
Business development in the middle and lower reaches. The diseases treated by umbilical cord blood stem cells in China are mainly hematological diseases, of which aplastic anemia accounts for 23%. β -thalassemia and acute myeloid leukemia accounted for 19% respectively. In the United States, the most commonly used umbilical cord blood is brain injury, accounting for 6 1%, followed by tumor, accounting for 17%. At present, the company has been exploring in the field of clinical application, and will strengthen R&D investment with the help of financial advantages in the future. Since 20 15, the policy on stem cell technology tends to be loose, which provides conditions for the development of stem cell industry in the middle and lower reaches. Under the double stimulation of policies and funds, the company will take the introduction of mature stem cell drugs and technologies as its long-term goal in the future, and at the same time, it will open up hospital links and carry out stem cell therapy to realize the integration of the middle and lower reaches of the industry.
At present, the most widely used stem cell therapy is nausea and tumor, with a market size of $27.7 billion, followed by diabetes with a market size of $20 billion.
The field of stem cell therapy continues to expand.
Stem cell technology has developed rapidly in recent years and has great clinical application potential in autoimmune diseases, central nervous system injury, cardiovascular diseases and so on. Moreover, the advantages of stem cell therapy are obvious, such as safety, sufficient sources of therapeutic materials and wide range of diseases. Many countries regard it as one of the important research and development directions. According to the published data, the clinical drugs for stem cells are all in the West.
However, in the process of scientific development and popularization of placental stem cells, many people still don't know much about the future prospects of such stem cells. Placental stem cells are a developing high-tech. In recent years, more and more scientific research results have been exported, which can help people better understand placental stem cells.
In recent years, placental stem cells have shown great clinical application potential in many diseases, including wound healing, ischemic heart disease, autoimmune diseases and chronic lung or liver injury.
China has been accepted by the Food and Drug Administration.
CFDA Drug Testing Center has accepted 65,438+07 applications for new stem cell drugs, but only two applications for new stem cell drugs are currently under trial. Although CFDA released the application for new stem cell drugs in China, it has not approved the stem cell clinical trials since April 38, 2065.
——? For more data, please refer to the Analysis Report on Market Prospect and Investment Potential of Stem Cell Therapy Technology Industry in China issued by Prospective Industry Research Institute.